APPLICATION OF CD38 INHIBITOR IN PREPARATION OF ANTI-RHEUMATOID ARTHRITIS DRUG

摘要

Provided is an application of a CD38 inhibitor in the preparation of an anti-rheumatoid arthritis (RA) drug. Studies have shown that the CD38+NK cell content and the ratio of CD38+NK / CD38+NKT in the blood and synovial fluid of an RA patient are increased, and such change is positively correlated with the DAS28 of the patient, indicating that CD38+NK cells and CD38+NKT cells are expected to become the therapeutic target of RA. Further research clearly shows that high levels of CD38+NK and a high ratio of CD38+NK / CD38+NKT in RA can reduce TGF-β secretion and activate the mTOR pathway of CD4+T cells in MNC, inhibiting the differentiation of CD4+T cells to differentiate Treg cells and IL-10 expression, increase the level of IFN-γ and the ratios of Thl/Th2 and Thl7/Treg, resulting in reduced anti-inflammatory and immune tolerance and exacerbating the course of RA.